Plain-English translation of NCT05086250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anxiety research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether , taken by mouth once a week, can help reduce anxiety in people with pancreatic cancer. Researchers want to see if this medication is safe, tolerable, and helpful for managing the significant anxiety that often comes with a cancer diagnosis and treatment. The study will enroll 20 participants and carefully track how well people tolerate the treatment and how their anxiety responds.
Many people diagnosed with pancreatic cancer experience moderate to severe anxiety during and after cancer treatment, and current treatment options may not work well enough for everyone. This trial explores whether this medication, which has shown promise for anxiety in other settings, could offer a new option for cancer patients who need better anxiety relief.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or placebo once per week for 4 weeks, then have a 2-week break, then take the other treatment for another 4 weeks. Half of participants start with the real medication first, and half start with placebo first—this helps researchers fairly compare the two. Throughout the study, you'll complete questionnaires about your anxiety, mood, pain, fatigue, and sleep, and may have blood drawn to measure inflammation and other markers. You cannot drive or operate machinery for the rest of the day after taking each dose, and you must avoid alcohol while taking the medication.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States